MedPath

Ezharmia Tablet Post-marketing Surveillance

Recruiting
Conditions
peripheral T-cell lymphoma: (PTCL)
Registration Number
jRCT2031240338
Lead Sponsor
Daiichi Sankyo Co.,Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
150
Inclusion Criteria

All patients who start receiving Ezharmia Tablet during the registration period.

Exclusion Criteria

None

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Cumulative incidence of AEs

safety specifications : myelosuppression, infection and the secondary malignancy of the survey

Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.